Butyrate's mechanisms: (1) Colonocyte fuel — enters mitochondria via β-oxidation, providing 70% of colonocyte ATP (healthy colonocytes preferentially use butyrate over glucose); (2) HDAC inhibition — butyrate is a class I/II histone deacetylase inhibitor, altering gene expression toward anti-inflammatory, anti-proliferative, and pro-apoptotic programs (this is the anti-cancer mechanism); (3) GPR41/GPR43/GPR109A receptor activation — these SCFA receptors on immune cells, enteroendocrine cells, and neurons mediate immune tolerance (Treg induction), GLP-1/PYY secretion (satiety), and gut-brain signaling; (4) tight junction protein upregulation — increases expression of claudins and occludin, strengthening the intestinal barrier; (5) mucosal blood flow increase — vasodilatory effects in colonic vasculature.
No critical interactions identified.
Independently graded against 173,636 indexed supplements with 177 published clinical interactions, sourced from PubMed, FDA CAERS, openFDA, and NIH DSLD | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.